Table 1 Patients clinico-pathological characteristics according to SLNB (n = 402)
From: Head and neck melanoma: outcome and predictors in a population-based cohort study
SLNB | χ2 | |||||||
|---|---|---|---|---|---|---|---|---|
no | yes | total | p | |||||
Count | % | Count | % | Count | % | |||
Sex | Male | 170 | 52.6% | 57 | 72.2% | 227 | 56.5% | 0.002 |
Female | 153 | 47.4% | 22 | 27.8% | 175 | 43.5% | ||
Age at diagnosis | < 50.0 | 51 | 15.8% | 21 | 26.6% | 72 | 17.9% | 0.006 |
50.0–59.9 | 47 | 14.6% | 12 | 15.2% | 59 | 14.7% | ||
60.0–69.9 | 68 | 21.1% | 12 | 15.2% | 80 | 19.9% | ||
70.0–79.9 | 95 | 29.4% | 30 | 38.0% | 125 | 31.1% | ||
≥ 80.0 | 62 | 19.2% | 4 | 5.1% | 66 | 16.4% | ||
CCI | 0 | 239 | 74.0% | 57 | 72.2% | 296 | 73.6% | 0.530 |
1 | 57 | 17.6% | 16 | 20.3% | 73 | 18.2% | ||
2 | 19 | 5.9% | 3 | 3.8% | 22 | 5.5% | ||
3 | 4 | 1.2% | 3 | 3.8% | 7 | 1.7% | ||
4 | 3 | 0.9% | 0 | 0.0% | 3 | 0.7% | ||
5 | 1 | 0.3% | 0 | 0.0% | 1 | 0.2% | ||
CCI classified | 0 | 239 | 74.0% | 57 | 72.2% | 296 | 73.6% | 0.739 |
≥ 1 | 84 | 26.0% | 22 | 27.8% | 106 | 26.4% | ||
Tumor localisation (ICD-10) | Lip skin (C44.0) | 2 | 0.6% | 0 | 0.0% | 2 | 0.5% | 0.062 |
Eyelid (C44.1) | 16 | 5.0% | 2 | 2.5% | 18 | 4.5% | ||
Outer ear (C44.2) | 44 | 13.6% | 17 | 21.5% | 61 | 15.2% | ||
Face (C44.3) | 163 | 50.5% | 28 | 35.4% | 191 | 47.5% | ||
Scalp and neck (C44.4) | 98 | 30.3% | 32 | 40.5% | 130 | 32.3% | ||
Tumor localisation | Face | 225 | 69.7% | 47 | 59.5% | 272 | 67.7% | 0.083 |
Scalp and neck | 98 | 30.3% | 32 | 40.5% | 130 | 32.3% | ||
UICC stage | IA | 214 | 66.3% | 5 | 6.3% | 219 | 54.5% | < 0.001 |
IB | 51 | 15.8% | 21 | 26.6% | 72 | 17.9% | ||
II | 48 | 14.9% | 43 | 54.4% | 91 | 22.6% | ||
III | 10 | 3.1% | 10 | 12.7% | 20 | 5.0% | ||
Histological subgroups | Lentigo maligna melanoma | 156 | 48.3% | 10 | 12.7% | 166 | 41.3% | < 0.001 |
Nodular melanoma | 34 | 10.5% | 27 | 34.2% | 61 | 15.2% | ||
Superficial spreading melanoma | 104 | 32.2% | 22 | 27.8% | 126 | 31.3% | ||
Melanoma not otherwise specified | 22 | 6.8% | 11 | 13.9% | 33 | 8.2% | ||
Other | 7 | 2.2% | 9 | 11.4% | 16 | 4.0% | ||
Tumor thickness (mm) | < 1 | 232 | 71.8% | 11 | 13.9% | 243 | 60.4% | < 0.001 |
1–2 | 39 | 12.1% | 26 | 32.9% | 65 | 16.2% | ||
2–4 | 28 | 8.7% | 16 | 20.3% | 44 | 10.9% | ||
> 4 | 24 | 7.4% | 26 | 32.9% | 50 | 12.4% | ||
Resection margin (mm) | < 5 | 83 | 25.7% | 12 | 15.2% | 95 | 23.6% | < 0.001 |
5–9 | 137 | 42.4% | 18 | 22.8% | 155 | 38.6% | ||
≥ 10 | 103 | 31.9% | 49 | 62.0% | 152 | 37.8% | ||
Adjuvant Chemo−/ Immunotherapy | yes | 12 | 3.7% | 6 | 7.6% | 18 | 4.5% | 0.135 |
no | 311 | 96.3% | 73 | 92.4% | 384 | 95.5% | ||
total | 323 | 100.0% | 79 | 100.0% | 402 | 100.0% | ||